- Clinical Trials
- April 2024
- 60 Pages
Global
From €1922EUR$2,000USD£1,652GBP
- Report
- October 2023
- 150 Pages
Global
From €4660EUR$4,850USD£4,007GBP
- Report
- May 2024
- 197 Pages
Global
From €4756EUR$4,950USD£4,090GBP
- Report
- January 2022
- 120 Pages
Global
From €4564EUR$4,750USD£3,924GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,197GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,264GBP
- Report
- May 2022
- 120 Pages
Global
From €2402EUR$2,500USD£2,066GBP
The Immunodeficiency Drugs market is a subset of the Immune Disorders Drugs market, which focuses on treatments for conditions that affect the body's ability to fight off infections. These drugs are used to treat a variety of conditions, including primary immunodeficiencies, secondary immunodeficiencies, and autoimmune diseases. Immunodeficiency drugs work by boosting the body's natural immune response, helping it to fight off infections more effectively. They can also be used to reduce the severity of symptoms associated with immune disorders.
Immunodeficiency drugs are typically administered orally or intravenously, depending on the condition being treated. Commonly used drugs include monoclonal antibodies, interferons, and cytokines. These drugs are used to treat a variety of conditions, including HIV/AIDS, cancer, and autoimmune diseases.
Some companies in the Immunodeficiency Drugs market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more
